Parkman Healthcare Partners LLC Has $4.21 Million Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Parkman Healthcare Partners LLC reduced its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 8.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,159 shares of the biopharmaceutical company's stock after selling 9,309 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 0.11% of Ultragenyx Pharmaceutical worth $4,214,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the company. Smartleaf Asset Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at $35,000. Human Investing LLC purchased a new stake in Ultragenyx Pharmaceutical in the 4th quarter worth $42,000. Van ECK Associates Corp grew its position in shares of Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares in the last quarter. Finally, Quarry LP purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter worth about $84,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares in the company, valued at approximately $2,358,014.08. The trade was a 5.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares in the company, valued at approximately $2,116,156.50. This represents a 1.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 125,405 shares of company stock valued at $5,285,169 over the last 90 days. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Trading Down 1.9%

RARE opened at $35.40 on Wednesday. The firm has a market capitalization of $3.35 billion, a PE ratio of -5.58 and a beta of 0.34. The firm has a 50 day moving average of $36.67 and a two-hundred day moving average of $42.11. Ultragenyx Pharmaceutical Inc. has a 12-month low of $29.59 and a 12-month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The firm had revenue of $139.29 million during the quarter, compared to analyst estimates of $145.98 million. During the same period last year, the business earned ($2.03) EPS. The firm's revenue was up 28.0% compared to the same quarter last year. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RARE has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. JPMorgan Chase & Co. raised their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. HC Wainwright reiterated a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Finally, Morgan Stanley lifted their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus target price of $90.93.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.